Adamis Pharmaceuticals Corporation
ADMP
$0.22
-$0.0001-0.05%
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 1.51M | 39.80K | 1.15M | -1.16M | 760.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.51M | 39.80K | 1.15M | -1.16M | 760.00K |
| Cost of Revenue | 1.65M | 689.20K | 1.46M | 1.66M | 1.57M |
| Gross Profit | -141.90K | -649.30K | -309.10K | -2.82M | -806.00K |
| SG&A Expenses | 2.51M | 4.21M | 3.38M | 4.43M | 4.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.13M | 8.22M | 9.07M | 8.29M | 10.98M |
| Operating Income | -4.63M | -8.18M | -7.91M | -9.45M | -10.22M |
| Income Before Tax | -4.27M | -8.34M | -10.19M | -7.81M | -5.17M |
| Income Tax Expenses | -- | -- | -- | 800.00 | -- |
| Earnings from Continuing Operations | -4.27M | -8.34M | -10.19M | -7.81M | -5.17M |
| Earnings from Discontinued Operations | -127.70K | -61.80K | -164.90K | -961.50K | -7.19M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.40M | -8.40M | -10.35M | -8.77M | -12.36M |
| EBIT | -4.63M | -8.18M | -7.91M | -9.45M | -10.22M |
| EBITDA | -4.23M | -7.81M | -7.57M | -9.08M | -9.85M |
| EPS Basic | -0.03 | -0.06 | -0.07 | -0.06 | -0.08 |
| Normalized Basic EPS | -0.02 | -0.04 | -0.03 | -0.04 | -0.04 |
| EPS Diluted | -0.03 | -0.06 | -0.07 | -0.06 | -0.08 |
| Normalized Diluted EPS | -0.02 | -0.04 | -0.03 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 149.98M | 149.82M | 149.62M | 149.18M | 148.89M |
| Average Diluted Shares Outstanding | 149.98M | 149.82M | 149.62M | 149.18M | 148.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
